Status:
COMPLETED
Patient Automated Text Hovering for IBD
Lead Sponsor:
University of Pennsylvania
Conditions:
Inflammatory Bowel Diseases
Crohn Disease
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
This is a 2-arm randomized trial aimed at leveraging behavioral science principles to improve patient engagement between office visits among patients with inflammatory bowel disease (IBD).
Detailed Description
Crohn's Disease (CD) and Ulcerative Colitis (UC), collectively known as inflammatory bowel disease (IBD), are common chronic gastrointestinal diseases with significant morbidity and decreased quality ...
Eligibility Criteria
Inclusion
- Diagnosis of Crohn's Disease or Ulcerative Colitis
- Has had at least 2 visits with Penn Gastroenterology in the past 2 years
- Currently prescribed a biologic therapy (infliximab, adalimumab, ustekinumab, certolizumab, golimumab, or vedolizumab). Of note, this study is not limited to new initiators of these medications.
Exclusion
- Patients will be excluded if they do not have a phone with text messaging.
Key Trial Info
Start Date :
February 23 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 10 2023
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04388865
Start Date
February 23 2021
End Date
January 10 2023
Last Update
February 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pennsylvania Health System
Philadelphia, Pennsylvania, United States, 19104